Literature DB >> 28757060

MMR and MMRV vaccines.

Frank Kowalzik1, Jörg Faber2, Markus Knuf3.   

Abstract

Measles, mumps, rubella and varicella are viral infections which can implicate seriously long-term sequelae of infected individuals or even the unborn child. Vaccines against the individual diseases have long been available. Global measles vaccination is estimated to have prevented more than 20million deaths during 2000-2015. During the same time period, measles incidence decreased from 146 to 36 cases per million populations. Today vaccinations against measles, mumps, rubella and varicella are now carried out mainly with combination vaccines. These are today known as immunogenic and safe. MMRV had similar immunogenicity and overall safety profiles to MMR administered with or without varicella vaccine. This issue provides a review of the different vaccines, mode of administration, catch up immunization and postexposure prophylaxis as well as contraindications and adverse effects of the immunization against measles, mumps, rubella, and varicella. The article presents an overview of important information of preventing these diseases with a focus on the existing combination vaccines.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MMR; MMRV; Measles; Mumps; Rubella; Vaccination; Varicella

Mesh:

Substances:

Year:  2017        PMID: 28757060     DOI: 10.1016/j.vaccine.2017.07.051

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

Review 2.  Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.

Authors:  Charles J Russell; Eric A F Simões; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2018-01-11       Impact factor: 2.257

3.  Immunization practices in children with a history of allergies.

Authors:  Hatice Ezgi Barış; Perran Boran; Ayça Kıykım; Safa Barış; Ahmet Özen; Elif Karakoç Aydıner
Journal:  Turk Pediatri Ars       Date:  2020-09-23

4.  Epidemiological changes in rubella IgG antibody levels detected in antenatal women from a retrospective rubella seroprevalence study.

Authors:  Ciara O'Connor; David Le Blanc; Richard J Drew
Journal:  Ir J Med Sci       Date:  2017-12-05       Impact factor: 2.089

Review 5.  Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.

Authors:  Jonas D Albarnaz; Alice A Torres; Geoffrey L Smith
Journal:  Viruses       Date:  2018-02-28       Impact factor: 5.048

6.  The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies.

Authors:  C Azzari; V Baldo; S Giuffrida; R Gani; E O'Brien; C Alimenti; V J Daniels; L J Wolfson
Journal:  Clinicoecon Outcomes Res       Date:  2020-06-08

7.  Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study.

Authors: 
Journal:  Hum Vaccin Immunother       Date:  2018-08-29       Impact factor: 3.452

8.  A retrospective 5-year review of rubella in South Africa prior to the introduction of a rubella-containing vaccine.

Authors:  Heather Hong; Susan Malfeld; Sheilagh Smit; Lillian Makhathini; Mirriam Fortuin; Tshepo Motsamai; Dipolelo Tselana; Morubula Jack Manamela; Nkengafac Villyen Motaze; Genevie Ntshoe; Mercy Kamupira; Ester Khosa-Lesola; Sibongile Mokoena; Thulasizwe Buthelezi; Elizabeth Maseti; Melinda Suchard
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

9.  Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom.

Authors:  Esse Ifebi Herve Akpo; Olivier Cristeau; Manjit Hunjan; Giacomo Casabona
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.